erythromycin stearate oral

6,000 6000 0% Off
Dosing & Uses

Dosing Form & Strengths


  • 250mg

General Dosing Recommendations

250 mg PO q6hr, OR

500 mg PO q12hr (if daily dose does not exceed 1 g)

May increase up to 4 g/day depending on infection severity


500 mg PO q6hr for 10-14 days

Legionnaires Disease

1-4 g/day PO in divided doses for 21 days


Urethritis caused by C trachomatis or U urealyticum

500 mg PO q6hr for 7 days; alternatively 333 mg PO q8hr for 7 days


30-40 g PO in divided doses for 10-15 days

Renal Impairment

Dose adjustment not necessary

Hepatic Impairment

Use caution

Other Indications & Uses

Group A beta-hemolytic strep, Actinobacillus actinomycetemcomitans, Actinomyces israelii, Actinomyces naeslundii, Actinomyces odontolyticus, Afipia felis, Arachnia propionica, Arcanobacterium (Corynebacterium) haemolyticum, Bacillus anthracis, Bartonella henselae, Bartonella quintana, Bordetella pertussis, Borrelia burgdorferi, Borrelia recurrentis, C. diphtheriae, C. trachomatis, Klebsiella granulomatis, Campylobacter jejuni, Capnocytophaga ochracea, Chlamydia pneumonia (TWAR agent), Chlamydia psittaci, Chlamydia trachomatis, Chryseobacterium meningosepticum, Corynebacterium jeikeium (CDC group JK), Corynebacterium minutissimum, Corynebacterium ulcerans, Coxiella burnetii, E. histolytica, Erysipelothrix rhusiopathiae, H. ducreyi, H. influenzae, Kingella sp., Lactobacillus sp, Legionella pneumophilia, Leptospira interrogans, Leptotrichia buccalis, Leuconostoc species, Listeria, Mycobacterium chelonae, Mycobacterium fortuitum, M. catarrhalis, Mycoplasma pneumoniae, N. gonorrhoeae, Rhodococcus equi, S. aureus, S. pyogenes (group A beta-hemolytic streptococci), S. pneumoniae, Spirillum minus, Streptobacillus moniliformis, Streptococcus (Group C, G), Streptococcus agalactiae (Group B), Streptococcus bovis (Group D), Streptococcus intermedius group (S. anginosus, S intermedius, S. constellatus), Streptococcus pneumoniae (PCN sensitive, MIC <0.1 mcg/mL), Streptococcus pyogenes (Group A), Treponema pallidum, U. urealyticum, Ureaplasma urealyticum, Vibrio cholerae, Viridans streptococci

Off-label: Campylobacter jejuni, Calymmatobacterium granulomatis, Haemophilus ducreyi, prophylaxis in colorectal surgery, anthrax, tetanus, Lyme disease

First line: Afipia felis, Arcanobacterium (Corynebacterium) haemolyticum, Bartonella henselae, Bartonella quintana, Campylobacter jejuni, Capnocytophaga ochracea, Chlamydia pneumonia, Corynebacterium minutissimum, Corynebacterium ulcerans, Haemophilus ducreyi, Mycobacterium fortuitum, Ureaplasma urealyticum (others eg, Haemophilus ducreyi not unanimous)

Adverse Effects


Abdominal pain (8%)

Headache (8%)

Nausea (8%)

Diarrhea (7%)

Rash (3%)

Vomiting (3%)

Dyspepsia (2%)

Flatulence (2%)

Pain (2%)

Pruritus (1%)

Pseudomembranous colitis

Hypertrophic pyloric stenosis



Mild allergic reactions


Skin eruptions



Cholestatic hepatitis



Hearing loss


Nervous system effects including seizures

Torsade de pointes

Ventricular tachycardia


Postmarketing reports

Interstitial nephritis



Documented hypersensitivity

Coadministration with terfenadine

Coadministration with HMG-CoA reductase inhibitors that are extensively metabolized by CYP3A4 (lovastatin or simvastatin)

Co-administration of erythromycin with pimozide, ergotamine or dihydroergotamine

Pregnancy & Lactation

Pregnancy Category: B

Lactation: distributed in breast milk, use with caution; AAP categorizes as compatible with breastfeeding

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.


C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.


D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.


X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.